文章基本信息

标题：TIMP3 promoter hypermethylation contributes to the risk of renal cell carcinoma: A meta-analysis
本地全文：下载
作者：Shijie Mo ; Zexuan Su ; Baoli Heng 等
期刊名称：Biomedical Research and Clinical Practice
电子版ISSN：2397-9631
出版年度：2017
卷号：2
期号：5
页码：1-7
DOI：10.15761-BRCP.1000152
语种：English
出版社：Open Access Text
摘要：Background/aim: The purpose of our study is to assess the association between the methylation level of tissue inhibitor of metalloproteinase-3 (TIMP3) and risk of renal cell carcinoma (RCC). Methods: A systematic review of relevant literature from PubMed, EMBASE, Web of Science, and the Cochrane Library databases was conducted. Odds ratio (OR) and its corresponding 95% confidence interval (CI) were calculated to analyze the data and acquire comprehensive results. Results: Ten eligible kinds of literature including 495 RCC specimens and 409 normal controls were analyzed in this meta-analysis. The results indicated that TIMP3 promoter hypermethylation was correlated with RCC-increased risk (OR=12.16, 95% CI: 3.64-40.66, PTIMP3 gene was related to low tumor stage (OR=2.77, 95% CI: 1.48-5.18, P=0.001). Conclusion: Our results suggested that the methylation level of TIMP3 promoter region was significant in RCC. Moreover, the finding is related to early tumor stage. The detection of TIMP3 promoter methylation may be a good strategy for the diagnosis of RCC at its early stages. Nevertheless, additional well-designed studies are needed to further prove our conclusion.
关键词：TIMP3; promoter; methylation; renal cancer; meta-analysis